Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma,
characterized by the ability of a subclone to thrive and grow independent of the bone …

Abstract Purpose of Review We discuss current topics on the definition of plasma cell
leukemia and the distinction between plasma cell leukemia and multiple myeloma …

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after
progress in the last decades. PCL deserves a prompt identification to start the most effective …

PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal
gammopathy. It was formerly characterized by≥ 20% circulating plasma cells (CTCs) until …

The introduction of novel agents in the management of multiple myeloma and related
plasma cell dyscrasias has changed our treatment approaches and subsequently the …

Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with a guarded
prognosis. The diagnosis is confirmed when peripheral blood plasma cells (PCs) exceed …

Plasma cell leukemia is a rare and aggressive plasma cell dyscrasia associated with dismal
outcomes. It may arise de novo, primary plasma cell leukemia, or evolve from an antecedent …

Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits
the ubiquitin proteasome pathway that leads to the degradation of many intracellular …

Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia that may appear
as de-novo leukemia (pPCL) or on the basis of a pre-existing multiple myeloma (MM), called …

PURPOSE Primary plasma cell leukemia (pPCL) is an aggressive subtype of multiple
myeloma, which is distinguished from newly diagnosed multiple myeloma (NDMM) on the …